The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse.
By A. Merlos-Suárez, Francisco M. Barriga, P. Jung, M. Iglesias, M. V. Céspedes, David Rossell, Marta Sevillano, Xavier Hernando-Momblona, Victoria da Silva-Diz, P. Muñoz and 4 more. Cell Stem Cell, 2011
945 citations recorded by the source corpus.
Subfields: Genetics, Oncology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/f0a57ec7eaf9c63b19e952a7690f68aa3e8731fe
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Florian Markowetz
- J. Massagué
- Louis Vermeulen
- S. Morrison
- E. Fessler
- E. Batlle
- J. Medema
- F. D. S. E. Melo
In Oncology
Citations in the corpus
- Dependency of colorectal cancer on a TGF-beta-driven programme in stromal cells for metastasis initiation (2012, background): “EPHB2-high tumor cells embedded in matrigel expanded as epithelial tumor organoids (Figure 5A), which retained high expression levels of colon stem cell marker genes such as LGR5 and ASCL2 (data not shown).”
- Evolution of the cancer stem cell model. (2014, background): “Recently, stemness signatures have been developed from normal stem cells in solid tissues including the intestine and breast (Merlos-Sua´rez et al., 2011; Pece et al., 2010).”
- Cancer stem cells: impact, heterogeneity, and uncertainty. (2012, background): “Some cancers, including hierarchically organized cancers that follow the stem cell model, can arise from normal stem cells through mutations that overactivate self-renewal mechanisms (Barker et al., 2009; Merlos-Suárez et al., 2011; Yang et al., 2008).”
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value (2013, methodology): “Each molecular subtype was further characterized according to (i) GEP of NT counterparts from our dataset; (ii) previously published supervised signatures based on intestinal stem cell phenotype [24,25], BRAF mutation [26], and serrated CRC phenotype [27], as described in Text S1; (iii) cancer-relev”